Professional Documents
Culture Documents
DOI 10.1007/s10875-015-0211-z
ORIGINAL ARTICLE
Received: 7 September 2015 / Accepted: 4 November 2015 / Published online: 14 November 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Introduction
Electronic supplementary material The online version of this article
Jacobsen syndrome (JS) is a contiguous gene syndrome
(doi:10.1007/s10875-015-0211-z) contains supplementary material,
which is available to authorized users. caused by partial deletion of the long arm of chromosome
11, and was initially described by the Danish physician dr.
* Virgil A. S. H. Dalm Petra Jacobsen in 1973 [1]. It is a rare disorder with estimated
v.dalm@erasmusmc.nl occurrence of about 1/100,000 births and a female to male
ratio of 2:1 [24]. JS is caused by partial deletions of the long
1
Department of Internal Medicine, Erasmus MC, s-Gravendijkwal
arm of chromosome 11, del(11)(q23) [1]. The deletion size
230, 3015 CE Rotterdam, The Netherlands ranges from 5 to 20 Mb. Breakpoints typically arise within
2
Department of Immunology, Erasmus MC, s-Gravendijkwal 230,
or distal to subband 11q23.3 and the deletion usually extends
3015 CE Rotterdam, The Netherlands to the telomere. Partial JS with a 5 Mb deletion has been
3
Department of Pediatric Infectious disease and Immunology,
described as well [2, 5].
Erasmus MC, s-Gravendijkwal 230, 3015 The most common clinical features include pre- and post-
CE Rotterdam, The Netherlands natal physical growth retardation, psychomotor retardation,
762 J Clin Immunol (2015) 35:761768
12 years [8] 12 years [9] 4 years [10] 5 years [10] 34 years [11] 45 years [12]
Clinical features Recurrent respiratory Chronic diarrhea, Recurrent respiratory Enterobacter Cloacae Increased incidence Recurrent pneumococcal
tract infections recurrent respiratory tract infections, mediastinitis, Klebsiella of viral and bacterial pneumoniae, genital and
tract infections otitis media, tracheitis, CNS bacteremia infections cutaneous condylomata
sinusitis
IgG 5,4 g/L (normal) 2,26 g/l (low) 2,81 g/l (low) 1,61 g/l (low) Not performed 3,4 g/l (low)
IgA 0,28 g/L (low) 0,31 g/l (low) 0,17 g/l (low) 0,19 g/l (low) Not performed 0,66 g/l (normal)
IgM 0,15 g/L (low) 0,06 g/l (low) 0,15 g/l (low) 0,25 g/l (low) 0,35 g/l (low) 0,40 g/l, (low)
Specific antibody titers Not performed Low Low Absent Not performed Low
against S. pneumoniae
Specific antibody titers Not performed Low Present Not performed Not performed Not performed
against H. influenzae
Antibody response upon Not performed Decreased Decreased Vaccinated, but no Not performed Decreased
vaccination with response measured
polysacharide vaccine
against S. pneumoniae
Antibody response upon Not performed Decreased Not performed Not performed Not performed Not performed
vaccination with
polysacharide-protein
conjugate vaccine
against H. Influenzae
Other laboratory findings Lymphopenia, Normal total numbers Lymphopenia Thrombocytopenia, Thrombocytopenia, lymphopenia
thrombocytopenia of B- and T-cells CD4+ T-cell penia, (low B-cells, CD4+ T-cells,
disturbed lymphocyte switched memory and
response to mitogens marginal zone B-cells)
This table summarizes clinical and immunological laboratory findings in 6 patients with Jacobsen syndrome described in literature [812]. Results depicted in bold represent abnormal findings when
compared to healthy controls. In between brackets interpretation of measured values when compared to healthy controls is described
IgG immunoglobulin, G, IgA immunoglobulin A, IgM immunoglobulin M
763
764 J Clin Immunol (2015) 35:761768
Table 2 Age, gender and genetic defects in our 6 patients with Jacobsen syndrome
1 24 M 11q- (45, x, ish der) (11) t (y;11) (p11.2;q24.1) (wcpyt)2 Recurrent otitis, sinusitis, upper and lower
respiratory tract infections
2 35 F Deletion 11q (q23.3 qter) No recurrent infections
3 14 F Deletion 11q (q.24.1-qter) Recurrent otitis, upper and lower respiratory
tract infections
4 14 M Deletion 11q 14.2 11q 22.2 Recurrent upper and lower respiratory tract
infections
5 6 F Deletion 11q (q23.3 qter) Recurrent otitis, sinusitis, upper and lower
respiratory tract infections
6 10 F Deletion 11q (q23.3 qter) Recurrent otitis, sinusitis, upper and lower
respiratory tract infections
This table shows the age, gender (F = female, M = male) and confirmed genetic abnormalities of the 6 Dutch patients with Jacobsen syndrome studied
Clinical Evaluation The results on total numbers of B, T and NK cells and the
levels of IgG, IgA and IgM are summarized in Table 3. In
In the present study we evaluated 6 patients with a summary, 5 out of 6 patients showed low levels of IgG. Low
genetically confirmed diagnosis of JS (see Table 2) for IgA levels were found in 2 and low IgM levels in 5 of the
an immunodeficiency. Five out of our 6 patients (all but patients. Total number of B cells were low in 4 out of 6 pa-
patient number 2 in Table 2) suffered from recurrent tients. Low numbers of T cells and NK cells were found in 2
upper and lower respiratory tract infections since early and 4 patients, respectively. Age-adjusted normal values for
childhood (otitis, sinusitis and pneumonia) for which IgG, IgA and IgM and total cell numbers are summarized in
repetitive antibiotic treatments and/or hospital admis- Supplemental Table 1.
sions were required. Although only few recorded data
over the past years were available, amongst others Specific Antibody Titres
H. influenzae and S. pneumoniae have been cultured
in a number of infectious episodes in these patients. Five out of 6 patients (patient 1,3,4,5,6) showed inappropriate
There were no patients that suffered from recurrent skin, responses against Pneumovax. All of these 5 patients also had
gastrointestinal tract, or urinary tract infections. Patient low total IgG levels (Table 3).
1 however, suffered from multiple and extensive warts
on hands and feet since approximately 3 years, for B Lymphocyte Subset Analysis
which he had received local treatment, without discern-
ible effect. There were no CT scans available from 5 By flowcytometry we investigated in more detail the B cell
out of 6 patients included, so we could not evaluate subsets (Table 4). We determined the absolute numbers of
whether any of these patients suffered from bronchiec- transitional B-cells (here defined as CD38high/CD24high); na-
tasis or other lung damage. The CT scan of one patient ive mature B-cells (CD38dim/CD24dim/IgD+/CD27); margin-
did not reveal any structural abnormalities of both al zone/natural effector B-cells (CD38dim/IgD+/CD27+) and
lungs. Two patients were already on immunoglobulin memory B-cells (CD38dim/IgD/CD27+) [20]. As shown in
supplementation therapy when analyzed. Patient 1 Table 3, the total number of B cells was low in 4 out of 6
started intravenous immunoglobulin supplementation patients studied. In more detail we found a decrease in the
therapy once every 4 weeks in 2011 at the age of 23. number of memory B cells in 5 out of 6 JS patients. In addi-
Patient 6 started subcutaneous immunoglobulin replace- tion, marginal zone like B cells were decreased in 4 patients.
ment in 2010 at the age of 6. The frequency of infec- Also the total numbers of CD4+ and CD8+ T cells were low in
tions decreased after immunoglobulin replacement ther- 1 and 2 patients, respectively. NK cells were below normal
apy. There were no signs of auto-immune disease or values in 4 patients. Importantly, CD38dimCD27+IgD- mem-
lymphoproliferation in any of these patients. There was ory B cells in patients with JS were extremely low when
no history of malignant diseases. compared to healthy controls (Fig. 1, p<0.05).
J Clin Immunol (2015) 35:761768 765
This table shows total numbers of B, T and NK cells (all 109 cells / l) and levels of IgG, IgA and IgM (all in g/l) in 6 patients with Jacobsen syndrome.
All values have been compared to normal values for age and are depicted in italic when normal for age and in bold when low for age. In supplementary
table 1, age-related normal values for total cell numbers and immunoglobulin levels have been summarized
Total numbers of various B cell and T cell subsets are presented for the 6 patients with JS. Numbers of cells are presented in cells/l. Bold numbers
indicate values that are lower than values in age-related healthy control values. In between brackets absolute numbers of cells for age-related healthy
controls are shown
766 J Clin Immunol (2015) 35:761768
patients with a confirmed diagnosis of JS. Early recogni- (CVID), which may assist with decisions to treat with intravenous
or subcutaneous immunoglobulin. Clin Exp Immunol.
tion of immunodeficiency leads to earlier therapeutic inter-
2013;174(2):20311.
vention, which results in prevention of recurrent infections 14. Ameratunga R, Brewerton M, Slade C, Jordan A, Gillis D, Steele R,
and subsequent organ damage. et al. Comparison of diagnostic criteria for common variable immu-
nodeficiency disorder. Front Immunol. 2014;5:415.
15. Jolles S. The variable in common variable immunodeficiency: a
disease of complex phenotypes. J Allergy Clin Immunol Pract.
2013;1(6):54556. quiz 57.
16. Driessen GJ, Ijspeert H, Weemaes CM, Haraldsson A, Trip M,
Open Access This article is distributed under the terms of the Creative Warris A, et al. Antibody deficiency in patients with ataxia telangi-
Commons Attribution 4.0 International License (http:// ectasia is caused by disturbed B- and T-cell homeostasis and re-
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, duced immune repertoire diversity. J Allergy Clin Immunol.
distribution, and reproduction in any medium, provided you give 2013;131(5):136775.e9.
appropriate credit to the original author(s) and the source, provide a link 17. Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al.
to the Creative Commons license, and indicate if changes were made. Laboratory diagnosis of specific antibody deficiency to pneumo-
coccal capsular polysaccharide antigens by multiplexed bead assay.
Clin Immunol. 2010;134(2):198205.
References 18. Bossuyt X, Borgers H, Moens L, Verbinnen B, Meyts I. Age- and
serotype-dependent antibody response to pneumococcal polysac-
charides. J Allergy Clin Immunol. 2011;127(4):107980. author
1. Jacobsen P, Hauge M, Henningsen K, Hobolth N, Mikkelsen M, reply 801.
Philip J. An (11;21) translocation in four generations with chromo- 19. Paris K, Sorensen RU. Assessment and clinical interpretation of
some 11 abnormalities in the offspring. A clinical, cytogenetical, polysaccharide antibody responses. Ann Allergy Asthma
and gene marker study. Hum Hered. 1973;23(6):56885. Immunol. 2007;99(5):4624.
2. Grossfeld PD, Mattina T, Lai Z, Favier R, Jones KL, Cotter F, et al. 20. Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M,
The 11q terminal deletion disorder: a prospective study of 110 Warris A, et al. B-cell replication history and somatic
cases. Am J Med Genet A. 2004;129A(1):5161. hypermutation status identify distinct pathophysiologic back-
3. Penny LA, DellAquila M, Jones MC, Bergoffen J, Cunniff C, grounds in common variable immunodeficiency. Blood.
Fryns JP, et al. Clinical and molecular characterization of patients 2011;118(26):681423.
with distal 11q deletions. Am J Hum Genet. 1995;56(3):67683. 21. Verbsky JW, Baker MW, Grossman WJ, Hintermeyer M, Dasu T,
4. Pivnick EK, Velagaleti GV, Wilroy RS, Smith ME, Rose SR, Tipton Bonacci B, et al. Newborn screening for severe combined immu-
RE, et al. Jacobsen syndrome: report of a patient with severe eye nodeficiency; the Wisconsin experience (20082011). J Clin
anomalies, growth hormone deficiency, and hypothyroidism asso- Immunol. 2012;32(1):828.
ciated with deletion 11 (q23q25) and review of 52 cases. J Med 22. Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp
Genet. 1996;33(9):7728. CD, Kurtycz DF, et al. Development of a routine newborn screen-
5. Bernaciak J, Szczaluba K, Derwinska K, Wisniowiecka-Kowalnik ing protocol for severe combined immunodeficiency. J Allergy Clin
B, Bocian E, Sasiadek MM, et al. Clinical and molecular- Immunol. 2009;124(3):5227.
cytogenetic evaluation of a family with partial Jacobsen syndrome 23. Kusters MA, Manders NC, de Jong BA, van Hout RW, Rijkers GT,
without thrombocytopenia caused by an approximately 5 Mb dele- de Vries E. Functionality of the pneumococcal antibody response in
tion del(11)(q24.3). Am J Med Genet A. 2008;146A(19):244954. Down syndrome subjects. Vaccine. 2013;31(52):62615.
6. Akshoomoff N, Mattson SN, Grossfeld PD. Evidence for autism 24. Verstegen RH, Driessen GJ, Bartol SJ, van Noesel CJ, Boon L, van
spectrum disorder in Jacobsen syndrome: identification of a candi- der Burg M, et al. Defective B-cell memory in patients with Down
date gene in distal 11q. Genet Med. 2015;17(2):1438. syndrome. J Allergy Clin Immunol. 2014;134(6):134653.e9.
7. Mattina T, Perrotta CS, Grossfeld P. Jacobsen syndrome. Orphanet 25. Ming JE, Graham Jr JR. Genetic syndromes with evidence of im-
J Rare Dis. 2009;4:9. mune deficiency. In: Sullivan KE, Stiehm ER, editors. Stiehms
8. Sirvent N, Monpoux F, Pedeutour F, Fraye M, Philip P, Ticchioni immune deficiencies. London: Academic; 2014. p. 281324.
M, et al. Jacobsens syndrome, thrombopenia and humoral immu- 26. Ming JE, Stiehm ER. Genetic syndromic immunodeficiencies with
nodeficiency. Syndrome de Jacobsen, thrombopenie et deficit antibody defects. Immunol Allergy Clin N Am. 2008;28(4):715
immunitaire humoral. Arch Pediatr. 1998;5(12):133840. 36. vii.
9. Fernandez-San Jose C, Martin-Nalda A, Vendrell Bayona T, Soler- 27. Kersseboom R, Brooks A, Weemaes C. Educational paper:
Palacin P. Hypogammaglobulinemia in a 12-year-old patient with syndromic forms of primary immunodeficiency. Eur J Pediatr.
Jacobsen syndrome. J Paediatr Child Health. 2011;47(7):4856. 2011;170(3):295308.
10. Puglisi G, Netravali MA, MacGinnitie AJ, Bonagura VR. 11q ter- 28. Ye M, Coldren C, Liang X, Mattina T, Goldmuntz E, Benson DW,
minal deletion disorder and common variable immunodeficiency. et al. Deletion of ETS-1, a gene in the Jacobsen syndrome critical
Ann Allergy Asthma Immunol. 2009;103(3):2678. region, causes ventricular septal defects and abnormal ventricular
11. von Bubnoff D, Kreiss-Nachtsheim M, Novak N, Engels E, Engels morphology in mice. Hum Mol Genet. 2010;19(4):64856.
H, Behrend C, et al. Primary immunodeficiency in combination 29. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, Lanier
with transverse upper limb defect and anal atresia in a 34-year-old LL, et al. The Ets-1 transcription factor is required for the develop-
patient with Jacobsen syndrome. Am J Med Genet A. ment of natural killer cells in mice. Immunity. 1998;9(4):55563.
2004;126A(3):2938. 30. Bories JC, Willerford DM, Grevin D, Davidson L, Camus A,
12. Seppanen M, Koillinen H, Mustjoki S, Tomi M, Sullivan KE. Martin P, et al. Increased T-cell apoptosis and terminal B-cell dif-
Terminal deletion of 11q with significant late-onset combined im- ferentiation induced by inactivation of the Ets-1 proto-oncogene.
mune deficiency. J Clin Immunol. 2014;34(1):1148. Nature. 1995;377(6550):6358.
13. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New 31. Eyquem S, Chemin K, Fasseu M, Bories JC. The Ets-1 transcription
diagnostic criteria for common variable immune deficiency factor is required for complete pre-T cell receptor function and
768 J Clin Immunol (2015) 35:761768
allelic exclusion at the T cell receptor beta locus. Proc Natl Acad Sci 37. Ramirez K, Chandler KJ, Spaulding C, Zandi S, Sigvardsson M,
U S A. 2004;101(44):157127. Graves BJ, et al. Gene deregulation and chronic activation in natural
32. Muthusamy N, Barton K, Leiden JM. Defective activation and sur- killer cells deficient in the transcription factor ETS1. Immunity.
vival of T cells lacking the Ets-1 transcription factor. Nature. 2012;36(6):92132.
1995;377(6550):63942. 38. Walunas TL, Wang B, Wang CR, Leiden JM. Cutting edge: the Ets1
33. Wang D, John SA, Clements JL, Percy DH, Barton KP, Garrett- transcription factor is required for the development of NK T cells in
Sinha LA. Ets-1 deficiency leads to altered B cell differentiation, mice. J Immunol. 2000;164(6):285760.
hyperresponsiveness to TLR9 and autoimmune disease. Int 39. Zhang XK, Moussa O, LaRue A, Bradshaw S, Molano I,
Immunol. 2005;17(9):117991. Spyropoulos DD, et al. The transcription factor Fli-1 modulates
34. Garrett-Sinha LA. Review of Ets1 structure, function, and roles in marginal zone and follicular B cell development in mice. J
immunity. Cell Mol Life Sci. 2013;70(18):337590. Immunol. 2008;181(3):164454.
35. Nguyen HV, Mouly E, Chemin K, Luinaud R, Despres R, Fermand 40. Ma SK, Wan TS, Au WY, Fung LF, So CK, Chan LC. Chromosome
JP, et al. The Ets-1 transcription factor is required for Stat1- 11q deletion in myeloid malignancies. Leukemia. 2002;16(5):9535.
mediated T-bet expression and IgG2a class switching in mouse B 41. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME,
cells. Blood. 2012;119(18):417481. Cunningham-Rundles C, et al. Primary immunodeficiency dis-
36. Higuchi T, Bartel FO, Masuya M, Deguchi T, Henderson KW, Li R, eases: an update on the classification from the international union
et al. Thymomegaly, microsplenia, and defective homeostatic pro- of immunological societies expert committee for primary immuno-
liferation of peripheral lymphocytes in p51-Ets1 isoform-specific deficiency. Front Immunol. 2014;5:162.
null mice. Mol Cell Biol. 2007;27(9):335366.